Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
J Clin Oncol. 2021 Aug 20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. Epub 2021 May 4.
J Clin Oncol. 2021.
PMID: 33945288
Clinical Trial.